Azithromycin to Modify Bronchiectasis Exacerbation Risk

NCT07608328 · tracked via the Priya Life Science Egypt tracker

Sponsor

Assiut University

Phase

Phase 4

Started

2026-06-29

Last updated

2026-09-24

Condition(s) studied

Non-cystic Fibrosis BronchiectasisBronchiectasis AdultBronchiectasisBronchiectasis With Acute Exacerbation

Investigational drug(s) / intervention(s)

Standard Bronchiectasis CareAzithromycin →Matching Placebo

Standard Bronchiectasis Care: Standard bronchiectasis care provided in both randomized groups according to institutional practice and treating physician judgment. Standard bronchiectasis care may include mucolytics, bronchodilators, chest physiotherapy, patient education, airway-clearance support, and treatment of acute exacerbations with antibiotics with or without systemic corticosteroids according to clinical indication. Standard bronchiectasis care is provided as shared background care in both arms and is not the randomized treatment contrast. Clinically required rescue or emergency care remains permitted according to treating physician judgment.

Azithromycin: Azithromycin 250 milligrams orally once daily for 12 months, added to standard bronchiectasis care.

Matching Placebo: Matching inert placebo tablet orally once daily for 12 months, added to standard bronchiectasis care. The placebo will not contain active azithromycin.

Study summary

The Azithromycin to Modify Bronchiectasis Exacerbation Risk (AMBER) trial is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial in adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB).

The trial evaluates whether azithromycin 250 mg orally once daily for 12 months, added to standard bronchiectasis care, reduces the occurrence of at least one bronchiectasis exacerbation during 12-month follow-up compared with matching placebo added to standard bronchiectasis care.

Participants will be randomized in a 1:1 allocation ratio to standard care plus matching placebo or standard care plus azithromycin. The primary analysis will follow the intention-to-treat (ITT) principle.

The AMBER trial is embedded within the Assiut University bronchiectasis translational research platform and is linked to the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework and the Bronchiectasis Phenotype Identification Model (BPIM). BASE and BPIM are not used for randomization stratification and will not modify the primary randomized comparison.

The locked Version 1.0 methodological disclosure document, protocol, and statistical analysis plan (SAP), primary sample-size source code, and endpoint-level sample-size support matrix are archived in Zenodo: https://doi.org/10.5281/zenodo.20178963.

The AMBER public preregistration is also available through the Open Science Framework (OSF) under Digital Object Identifier (DOI) 10.17605/OSF.IO/RE54V.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult patients aged 18 years or older. * Clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB). * Diagnosis supported by clinical assessment and high-resolution computed tomography (HRCT). * Patients attending outpatient clinics, inpatient wards, respiratory follow-up services, or routine bronchiectasis care pathways at Assiut University Hospitals during the enrollment period. * Suitable for baseline disease-signature assessment. * Able to undergo protocol-defined clinical, functional, radiological, oxygenation, inflammatory, symptom, and safety assessment. * Able to complete planned 12-month follow-up. * Eligible for randomization after baseline safety evaluation. * Written informed consent obtained from the participant or legal representative. Exclusion Criteria: * Cystic fibrosis-related bronchiectasis. * Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis. * Active pulmonary tuberculosis at enrollment. * Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment. * Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up. * Acute life-threatening illness preventing safe enrollment, baseline assessment, or randomization. * Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment. * Known hypersensitivity, contraindication, or serious intolerance to azithromycin or macrolide therapy. * Baseline cardiac findings judged by the investigator to make long-term azithromycin unsafe. * Requirement for long-term maintenance macrolide therapy at enrollment. * Current long-term maintenance macrolide use that cannot be safely discontinued before enrollment. * Inability to complete required baseline disease-signature assessment. * Inability or unwillingness to complete planned 12-month follow-up. * Refusal to participate.

Primary outcome measure(s)

Occurrence of at Least One Bronchiectasis Exacerbation During 12-Month Follow-Up — Baseline to 12 months follow-up.
Assessment of the proportion of participants who experience at least one qualifying bronchiectasis exacerbation during 12-month follow-up. Randomized treatment assignment compares standard bronchiectasis care plus azithromycin with standard bronchiectasis care plus matching placebo. A qualifying exacerbation requires both clinically significant worsening of bronchiectasis-related respiratory symptoms and initiation or escalation of acute therapy. Lower occurrence indicates better clinical outcome and favors azithromycin. Unit of measure: percentage of participants.

Trial sites (1)

Facility	City	Region	Status
Assiut university-Faculty of Medicine	Asyut	Egypt	Recruiting

On this site

📄 Zithromax (azithromycin) drug profile →

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting

The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon

Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon

Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon

Intraoperative Lidocaine Infusion Starting soon

Other trials for the same condition

HFNC in Management of Bronchiectasis Exacerbation Recruiting

Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases Recruiting

Bronchiectasis Phenotype Identification Model Recruiting

Sleep Quality in Patients With Non-cystic Fibrosis Bronchiectasis Active, not recruiting

Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07608328 on ClinicalTrials.gov ↗ ← All trials in Egypt